Healthcare provider profile · identity verified

Daniel A Hoit, MD

Allopathic & Osteopathic Physicians|Neurological Surgery · MEMPHIS, TN · NPI 1902000698

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Daniel A Hoit, MD received $41,491.78 in general payments during 2025 across 97 reported records.

Stryker Corporation accounted for 35.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 21 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$41,491.78

97 reported records · 12 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Stryker Corporation Unresolved — no canonical attribution shown $14,540.4635.0%262025
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22
$13,013.9531.4%372025
Siemens Medical Solutions USA, Inc. Unresolved — no canonical attribution shown $12,591.4730.4%62025
Imperative Care, Inc Unresolved — no canonical attribution shown $466.631.1%162025
MicroVention, Inc. Unresolved — no canonical attribution shown $165.170.4%12025
Zimmer Biomet Holdings, Inc. Unresolved — no canonical attribution shown $162.760.4%22025
DePuy Synthes Sales Inc. Unresolved — no canonical attribution shown $149.150.4%42025
Abbott Laboratories Unresolved — no canonical attribution shown $108.550.3%12025
Globus Medical, Inc. Unresolved — no canonical attribution shown $102.090.2%12025
QAPEL MEDICAL INC Unresolved — no canonical attribution shown $80.320.2%12025
Boston Scientific Corporation Unresolved — no canonical attribution shown $58.150.1%12025
Route 92 Medical, Inc. Unresolved — no canonical attribution shown $53.080.1%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Consulting Fee$25,150.0029
Travel and Lodging$13,655.535
Food and Beverage$2,686.2563

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
TREVO
Normalized: trevo
Device Stryker Corporation $12,413.81 3 2025
Source payment records
CATALYFT PL EXPANDABLE INTERBODY SYSTEM
Normalized: catalyft pl expandable interbody system
Device Medtronic, Inc. $8,700.00 21 2025
Source payment records
SURPASS EVOLVE
Normalized: surpass evolve
Device Stryker Corporation $1,115.08 12 2025
Source payment records
ZOOM 88-T LARGE DISTAL PLATFORM
Normalized: zoom 88 t large distal platform
Device Imperative Care, Inc $360.39 13 2025
Source payment records
BROADWAY 8
Normalized: broadway 8
Device Stryker Corporation $281.91 8 2025
Source payment records
Artis pheno
Normalized: artis pheno
Device Siemens Medical Solutions USA, Inc. $191.47 5 2025
Source payment records
WEB ANEURYSM EMBOLIZATION SYSTEM
Normalized: web aneurysm embolization system
Device MicroVention, Inc. $165.17 1 2025
Source payment records
INTELLIS ADAPTIVESTIM
Normalized: intellis adaptivestim
Device Medtronic, Inc. $159.53 5 2025
Source payment records
NEURO PLATING SYSTEM
Normalized: neuro plating system
Device Zimmer Biomet Holdings, Inc. $120.90 1 2025
Source payment records
ETERNA
Normalized: eterna
Device Abbott Laboratories $108.55 1 2025
Source payment records
TARGET
Normalized: target
Device Stryker Corporation $108.18 5 2025
Source payment records
ZOOM REPERFUSION CATHETER
Normalized: zoom reperfusion catheter
Device Imperative Care, Inc $106.24 3 2025
Source payment records
ONYX 18
Normalized: onyx 18
Device Medtronic, Inc. $88.69 1 2025
Source payment records
SYNCHRO SELECT
Normalized: synchro select
Device Stryker Corporation $77.90 1 2025
Source payment records
WINGSPAN
Normalized: wingspan
Device Stryker Corporation $77.90 1 2025
Source payment records
EMBOGUARD
Normalized: emboguard
Device DePuy Synthes Sales Inc. $76.99 2 2025
Source payment records
TRUFILL
Normalized: trufill
Device DePuy Synthes Sales Inc. $72.16 2 2025
Source payment records
CDS - MCT/CEM Monitoring
Normalized: cds mct cem monitoring
Device Boston Scientific Corporation $58.15 1 2025
Source payment records
EVO SEEG ELECTRODE
Normalized: evo seeg electrode
Device Zimmer Biomet Holdings, Inc. $41.86 1 2025
Source payment records
SYNCHROMEDII
Normalized: synchromedii
Device Medtronic, Inc. $12.16 2 2025
Source payment records
INCEPTIV
Normalized: inceptiv
Device Medtronic, Inc. $3.57 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3529
ClopidogrelClopidogrel Bisulfate3013
GabapentinGabapentin14suppressed
BrilintaTicagrelor11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $41,491.78 · 97 records Stryker Corporation Artis pheno, BROADWAY 8, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, CDS - MCT/CEM Monitoring, EMBOGUARD, ETERNA, EVO SEEG ELECTRODE, INCEPTIV, INTELLIS ADAPTIVESTIM, NEURO PLATING SYSTEM, ONYX 18, SURPASS EVOLVE, SYNCHRO SELECT, SYNCHROMEDII, TARGET, TREVO, TRUFILL, WEB ANEURYSM EMBOLIZATION SYSTEM, WINGSPAN, ZOOM 88-T LARGE DISTAL PLATFORM, ZOOM REPERFUSION CATHETER
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error